Medicalize
Me: Experts look at perceptions of illness
Newswise — Do prescription drug
ads make people think they’re sick when they’re not,
or create “disease” out of thin air? Does the
“empowered patient” movement mean that doctors have
lost some of their professional clout when it comes
to making diagnoses and prescribing treatment?
These questions and more are
the focus of a set of probing essays in a special
section of the Feb. 24 issue of the journal The
Lancet, all addressing the topic of “medicalization”
and what it means in modern society.
The essays, which grew out of
an international workshop, zero in on the fact that
even the word “medicalization” has a different
meaning today than 30 years ago.
“When the term first came into
use in the 1970s, it was used critically to mean the
‘evil’ actions of doctors who turned deviation from
the norm into disease, and imposed medical authority
on aspects of everyday life such as birth, aging or
dying,” says Jonathan Metzl, M.D., Ph.D., a
University of Michigan Medical School psychiatrist
and U-M women’s studies researcher who co-organized
the workshop and wrote or co-wrote two of the six
Lancet articles. “But today, it’s used more in
connection with the actions of pharmaceutical
companies, and we need to understand its effects
better.”
The six essays focus on the
intersections between medicine and society,
including the role of the physician and the patient,
and of the values, wants and needs that each doctor
or patient brings to each interaction.
Metzl co-authored the
introduction with Rebecca M. Herzig, Ph.D., a
professor in Women and Gender Studies at Bates
College in Maine who worked with him to organize the
workshop. They report that a Google search for the
term “medicalization” (and its British spelling, “medicalisation”)
yields more than 358,000 hits –most of which have to
do with the drug industry’s role in changing
societal perceptions of disease, “normalcy” and
wellness.
But the authors also warn
against painting this phenomenon with an entirely
negative brush. “The same drugs that treat deviances
from social norms also help many people live their
lives,” they write. While the old definition of
“medicalization” painted patients as the victims,
the new model gives them the opportunity to be
advocates and choosy consumers – if they and their
doctors discuss openly their beliefs about what they
think the drug from the television advertisement
will do for them.
Metzl examines the impact of
direct-to-consumer drug advertising even further, in
an essay on what Europeans can learn from Americans’
ten-year experience with the ads if Britain and
European countries decided to allow them too.
“Is it the case that our
notions of illness are created by the pharmaceutical
industry’s advertising, or is it also the case that
drug companies are reflecting societal
expectations?,” Metzl asks. “Culture plays a large
role in this process, and the drug companies aren’t
just inventing this from scratch. They’re playing to
a market that’s used to asking for things from their
doctors, and it’s raising very interesting questions
of interpersonal dynamics.”
Metzl and other writers of
essays in the special section look to history to
shed light on the current situation. Metzl is the
author of a 2003 book “Prozac on the Couch:
Prescribing Gender in the Era of Wonder Drugs,”
which examined how depression and anxiety
medications were represented in advertising aimed at
physicians, and in the entertainment media, in the
latter half of the 20th century.
Today’s ads amplify people’s
cultural expectations, or even change them, he says
in the new essay – for instance, erectile
dysfunction drug ads that are featured prominently
at sporting events as well as on TV play to men’s
perceptions of what it is to be a normal, healthy
man. The same goes for antidepressant ads showing
women who are able to fulfill their roles and duties
as mothers.
What people do in response to
these ads is another aspect to the medicalization
issue, Metzl says. Studies have shown that patients
who go to their doctors and ask for a medicine they
saw in an advertisement are likely to get it –
which, of course, is part of the reason the blitz of
ads has escalated every year since the U.S. Food &
Drug Administration relaxed the rules for them in
1997.
But this has led to a kind of
tension in the interaction between doctors and
patients that is new, Metzl notes, as physicians try
to decide whether to say yes or no to each request.
The fact that physicians themselves are exposed to
the same ads, and are part of the same society as
their patients, further complicates the issue.
The answer for U.S. doctors,
and for the British and European doctors who may
soon find themselves in the same position as their
American counterparts, may be to bring the social
issues directly into their conversations with
patients, Metzl explains. “If a problem is being
medicalized, we need to look at what else we can do
as physicians besides blaming drug companies, and
talk to patients about what else they need to be
aware of and what may be driving their response to
an ad,” he says. “Doctors and patients shouldn’t
mindless follow the suggestions of drug ads, but
they should talk about the options and the
expectations that they have, and how realistic those
expectations may be – and then decide whether the
medicine is right.”
In addition to Metzl and Hertzig, the essay section
features writings by Nancy Tomes, of the history
department at the State University of New York at
Stony Brook, writing on patient empowerment and the
dilemmas of today’s medicalization; Nikolas Rose of
the London School of Economics, who looks at the
history and future of medicalization; Troy Duster of
New York University, who examines the medicalization
of race including medicines that are being aimed at
members of certain ethnic groups; and Cindy Patton
of Simon Fraser University in Vancouver, who looks
at the specific issue of medicalization in the
treatment of HIV/AIDS.
The workshop that led to the
writing and publication of the essays was funded by
grants from the University of Michigan, the Charles
Engelhard Foundation, and Bates College.